Regeneron Pharmaceuticals Inc. Chief Executive Officer Leonard Schleifer took direct aim at a fellow CEO Nov. 30, saying that Allergan Plc’s recent attempt to defend a drug patent by transferring it to native American tribe was a desperate move.
“It’s nuts,” Schleifer said at a health conference hosted by Forbes in New York. Turning to Allergan CEO Brent Saunders, who was sitting to his right, Schleifer added: “It makes your company look bad. It makes it look desperate to circumvent our system by licensing.”
Saunders disagreed, blaming a problematic legal and patent system for his company’s decision.
“The reality is, ...